All In Biotech

Drug Trial Radar · NCT07468851

A Study of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radical Cystectomy

A Phase I/II Clinical Study Evaluating the Safety, Efficacy, Tolerability, and Pharmacokinetics of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radical Cystectomy

Last checked: Nov 19, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

180

Planned (sponsor's estimate)

Start

Aug 5, 2026

Primary completion

Apr 30, 2028

Study completion Apr 30, 2029

Sponsor

Sponsor type
Industry
First posted
Mar 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label, Phase I/II clinical study evaluating the safety, efficacy, tolerability, and pharmacokinetic/pharmacodynamic (PK/PD) profiles of HS-10566 in patients with high-risk non-muscle-invasive bladder cancer who are ineligible for or refuse radical cystectomy. The study comprises two distinct phases: a dose exploration phase and a proof-of-concept phase.

Conditions

  • High-risk Non-muscle-invasive Bladder Cancer

Interventions

  • HS-10566Drug

    HS-10566 is an intravesical gemcitabine delivery system available in two drug-loaded strengths: 0.3 g gemcitabine and 0.6 g gemcitabine.

  • HS-10566Drug

    HS-10566 is an intravesical gemcitabine delivery system available in two drug-loaded strengths: 0.3 g gemcitabine and 0.6 g gemcitabine.

  • HS-10566Drug

    HS-10566 is an intravesical gemcitabine delivery system available in two drug-loaded strengths: 0.3 g gemcitabine and 0.6 g gemcitabine.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase I: RP2DTime frame: Up to 5 months
  2. Phase II Arm 1: overall complete response (CR) rateTime frame: Up to 36 months
  3. Phase II Arm 2: disease-free survival (DFS)Time frame: Up to 36 months
  4. Phase II Arm 3: event-free survival (EFS)Time frame: Up to 36 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Peking University First Hospital

    Beijing, China · Recruiting

  • Nanjing Drum Tower Hospital

    Nanjing, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.